BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 29748183)

  • 1. Aberrant Lck Signal via CD28 Costimulation Augments Antigen-Specific Functionality and Tumor Control by Redirected T Cells with PD-1 Blockade in Humanized Mice.
    Gulati P; Rühl J; Kannan A; Pircher M; Schuberth P; Nytko KJ; Pruschy M; Sulser S; Haefner M; Jensen S; Soltermann A; Jungraithmayr W; Eisenring M; Winder T; Samaras P; Tabor A; Stenger R; Stupp R; Weder W; Renner C; Münz C; Petrausch U
    Clin Cancer Res; 2018 Aug; 24(16):3981-3993. PubMed ID: 29748183
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells.
    Schuberth PC; Hagedorn C; Jensen SM; Gulati P; van den Broek M; Mischo A; Soltermann A; Jüngel A; Marroquin Belaunzaran O; Stahel R; Renner C; Petrausch U
    J Transl Med; 2013 Aug; 11():187. PubMed ID: 23937772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo.
    Song DG; Ye Q; Poussin M; Harms GM; Figini M; Powell DJ
    Blood; 2012 Jan; 119(3):696-706. PubMed ID: 22117050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors.
    Moon EK; Wang LC; Dolfi DV; Wilson CB; Ranganathan R; Sun J; Kapoor V; Scholler J; Puré E; Milone MC; June CH; Riley JL; Wherry EJ; Albelda SM
    Clin Cancer Res; 2014 Aug; 20(16):4262-73. PubMed ID: 24919573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity.
    Adusumilli PS; Cherkassky L; Villena-Vargas J; Colovos C; Servais E; Plotkin J; Jones DR; Sadelain M
    Sci Transl Med; 2014 Nov; 6(261):261ra151. PubMed ID: 25378643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1).
    Petrausch U; Schuberth PC; Hagedorn C; Soltermann A; Tomaszek S; Stahel R; Weder W; Renner C
    BMC Cancer; 2012 Dec; 12():615. PubMed ID: 23259649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracavitary 'T4 immunotherapy' of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells.
    Klampatsa A; Achkova DY; Davies DM; Parente-Pereira AC; Woodman N; Rosekilly J; Osborne G; Thayaparan T; Bille A; Sheaf M; Spicer JF; King J; Maher J
    Cancer Lett; 2017 May; 393():52-59. PubMed ID: 28223167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.
    Combaz-Lair C; Galateau-Sallé F; McLeer-Florin A; Le Stang N; David-Boudet L; Duruisseaux M; Ferretti GR; Brambilla E; Lebecque S; Lantuejoul S
    Hum Pathol; 2016 Jun; 52():9-18. PubMed ID: 26980049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
    Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
    Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition.
    Cherkassky L; Morello A; Villena-Vargas J; Feng Y; Dimitrov DS; Jones DR; Sadelain M; Adusumilli PS
    J Clin Invest; 2016 Aug; 126(8):3130-44. PubMed ID: 27454297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD28 costimulation Impairs the efficacy of a redirected t-cell antitumor attack in the presence of regulatory t cells which can be overcome by preventing Lck activation.
    Kofler DM; Chmielewski M; Rappl G; Hombach A; Riet T; Schmidt A; Hombach AA; Wendtner CM; Abken H
    Mol Ther; 2011 Apr; 19(4):760-7. PubMed ID: 21326215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity.
    Wang LC; Lo A; Scholler J; Sun J; Majumdar RS; Kapoor V; Antzis M; Cotner CE; Johnson LA; Durham AC; Solomides CC; June CH; Puré E; Albelda SM
    Cancer Immunol Res; 2014 Feb; 2(2):154-66. PubMed ID: 24778279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antigen spreading-induced CD8+T cells confer protection against the lethal challenge of wild-type malignant mesothelioma by eliminating myeloid-derived suppressor cells.
    Yu Z; Tan Z; Lee BK; Tang J; Wu X; Cheung KW; Lo NT; Man K; Liu L; Chen Z
    Oncotarget; 2015 Oct; 6(32):32426-38. PubMed ID: 26431275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. THEMIS-SHP1 Recruitment by 4-1BB Tunes LCK-Mediated Priming of Chimeric Antigen Receptor-Redirected T Cells.
    Sun C; Shou P; Du H; Hirabayashi K; Chen Y; Herring LE; Ahn S; Xu Y; Suzuki K; Li G; Tsahouridis O; Su L; Savoldo B; Dotti G
    Cancer Cell; 2020 Feb; 37(2):216-225.e6. PubMed ID: 32004441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
    Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
    Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
    [No Abstract]   [Full Text] [Related]  

  • 16. CD28 Costimulatory Domain-Targeted Mutations Enhance Chimeric Antigen Receptor T-cell Function.
    Boucher JC; Li G; Kotani H; Cabral ML; Morrissey D; Lee SB; Spitler K; Beatty NJ; Cervantes EV; Shrestha B; Yu B; Kazi A; Wang X; Sebti SM; Davila ML
    Cancer Immunol Res; 2021 Jan; 9(1):62-74. PubMed ID: 33188139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2
    Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE
    Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641
    [No Abstract]   [Full Text] [Related]  

  • 18. CAR T-cell therapy for lung cancer and malignant pleural mesothelioma.
    Zeltsman M; Dozier J; McGee E; Ngai D; Adusumilli PS
    Transl Res; 2017 Sep; 187():1-10. PubMed ID: 28502785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trametinib plus 4-Methylumbelliferone Exhibits Antitumor Effects by ERK Blockade and CD44 Downregulation and Affects PD-1 and PD-L1 in Malignant Pleural Mesothelioma.
    Cho H; Matsumoto S; Fujita Y; Kuroda A; Menju T; Sonobe M; Kondo N; Torii I; Nakano T; Lara PN; Gandara DR; Date H; Hasegawa S
    J Thorac Oncol; 2017 Mar; 12(3):477-490. PubMed ID: 27867002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Excessive Costimulation Leads to Dysfunction of Adoptively Transferred T Cells.
    Wijewarnasuriya D; Bebernitz C; Lopez AV; Rafiq S; Brentjens RJ
    Cancer Immunol Res; 2020 Jun; 8(6):732-742. PubMed ID: 32213625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.